| HOME >> BIOLOGY >> TECHNOLOGY |
BOSTON, Sept. 4 /PRNewswire/ -- The Cytokine Institute (TCI), a Los Angeles-based DNA and genomics research and consulting group, announced today the opening of a new office in the heart of Boston's legal and financial district. The organization measures and analyzes the effects of chemical and toxic exposures on human health and the environment. Through its Boston-based consulting arm, Green Reach Consulting, TCI now offers a range of business, financial, litigation, and industrial consulting services focused on toxic tort issues, as well as environmental, healthcare, chemical, and hazard management.
The Cytokine Institute, founded by medical toxicologist Bruce Gillis, M.D., M.P.H, pioneered the genomics-based technology, msds1(TM), in concert with the faculty and staff of the University of Illinois College of Medicine. The technology analyzes how 36,000 parameters of an individual's DNA are affected by specific chemicals -- including benzene, chromium, asbestos and formaldehyde.
It is the first DNA evidence of its kind to be used in civil court, enabling attorneys and judges to weed out baseless and frivolous lawsuits while providing scientific evidence in support of those who have in fact suffered injury. Companies facing class-action lawsuits are now benefiting from TCI's technology and protocols.
"For the first time, we can now apply an impartial methodology for providing scientifically-based evidence in liability and workers compensation cases," said Dr. Gillis. "By eliminating our justice system's dependence on circumstantial evidence and often-unreliable expert witnesses, the technology's potential benefits for healthcare, insurance and tort litigation are profound."
The technology is currently being used in numerous workers compensation cases pending in California. Insurers, chemical companies, law firms and the American Bar Association are carefully watching its development for further use in courtrooms around the country.
'/>"/>| SOURCE The Cytokine Institute Copyright©2007 PR Newswire. All rights reserved |